KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.35
−11.30%Year over year
Reported trailing growth
- Revenue
- +6.8%
- EBITDA
- —
- EBIT
- +28.5%
- EPS
- -52.8%
- Free cash flow
- +36.5%
- Operating cash flow
- +36.5%
Forward estimates
Based on analyst estimates
- Revenue
- +2.8%
- EBITDA
- +84.2%
- EPS
- +87.8%
Three-year CAGR
- Revenue
- -2.4%
- EBITDA
- —
- EBIT
- +24.1%
- Net income
- —
- EPS
- -90.5%
- Free cash flow
- +40.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026